I woke up with squiggly lines and dots in my eyesight. They are eye floaters and pretty common despite being annoying.

It can cause blurred vision, floaters, and even blindness ... Exams Regular comprehensive eye exams are essential for detecting eye problems early, even before you experience any symptoms. Early ...

THEY may be the window to your soul, but it turns out your eyes can also be a window to your overall health. While your ...

This condition may require a number of rounds of treatment but is usually permanent, as is cosmetic alteration. Both keratopigmentation and laser depigmentation hold significant risk of infection as ...

If you happen to get sick, it’s understandable to wonder about the current COVID symptoms in 2024—and if you might have the virus. After all, today’s COVID-19 is very different from what it ...

A doctor has taken to social media to highlight some of the symptoms that people may dismiss ... The medical professional says that people with 'floaters' will see 'squiggly worms' when looking ...

In May of 2023, there was a massive advance in the world of organ transplantation: the first whole human eye and partial face transplant. The man at the center of this procedure is 46-year-old Aaron ...

The new vessel networks can break, leading to bleeding inside your eye and other complications. Sickle cell retinopathy may not cause symptoms in the early stages. For that reason, regular ...

Laughter may be as effective as eye drops in improving symptoms of dry eye disease, finds a clinical trial from China published by The BMJ today. The researchers suggest that laughter exercise ...

We brought all the tools and heavy weapons into the picture to get this done. I think this project has opened eyes, including at the NSF Polar Program. This project triggered the chain reaction ...

Veligrotug helped 64% of patients, when adjusted for placebo rates, achieve at least a 2-millimeter reduction in eye bulging after 15 weeks of treatment, Viridian said. The company said 5.5% of ...

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to ...